TITLE

SEMBIOSYS GETS ALBERTA AWARD FOR PLANT BIOTECHNOLOGY

PUB. DATE
December 2002
SOURCE
Worldwide Biotech;Dec2002, Vol. 14 Issue 12, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the Alberta Science and Technology Award for Innovation in Industrial Research Prize received by biotechnology company SemBioSys Genetics Inc. for its contributions to plant biotechnology.
ACCESSION #
8573857

 

Related Articles

  • A bean counter's take on human resources. Watson, Paul // Nature Biotechnology;Jun2004, Vol. 22 Issue 6, p783 

    SemBioSys Genetics Inc. of Calgary, Alberta, Canada is pushing the frontiers of what is possible in biotechnology by fundamentally changing the way proteins are made. The large investments made in immunology, genomics, high-throughput molecular screening and other technologies in the 1990s are...

  • Generex Gears Up For Phase III Trial Of Oral-lyn Insulin Spray. Boggs, Jennifer // BioWorld Today;6/27/2007, Vol. 18 Issue 124, p3 

    The article discusses the highlights of the American Diabetes Association meeting held in Chicago, Illinois. Generex Biotechnology Corp. announced its plans to start a pivotal Phase III trial of its oral insulin spray product in patients with Type I diabetes mellitus. SemBioSys Genetics Inc....

  • OTHER NEWS TO NOTE.  // BioWorld Today;12/29/2008, Vol. 19 Issue 250, p2 

    This section offers news briefs on the biotechnology industry as of December 29, 2008. Pharmacopeia Inc. has been acquired by Ligand Pharmaceuticals Inc. of San Diego, California. An option for $2.5 million to license rights to plant-produced recombinant human insulin from SemBioSys Genetics...

  • Global News Network.  // BioPharm International;Jun2005, Vol. 18 Issue 6, p20 

    Reports global developments related to the pharmaceutical industry. Competitiveness of European countries in biotechnology research; Research of Israel-based, The Endocrine Institute, in the design of adult liver cells to produce insulin; Recognition of SemBioSys Genetics Inc., with the Company...

  • CLINIC ROUNDUP.  // BioWorld Today;3/27/2008, Vol. 19 Issue 60, p2 

    This section offers news briefs related to the biotechnology industry. Metabolex Inc. announced that it has dosed the first cohort of healthy subjects in a Phase I clinical trial of MBX-2982, a potential treatment for Type II diabetes. Nventa Biopharmaceuticals Corp. revealed interim...

  • Financings Roundup.  // BioWorld Today;2/22/2011, Vol. 22 Issue 35, p3 

    The article reports on the modification made by SemBioSys Genetics Inc. on its proposed 4 million dollar financing.

  • FINANCINGS ROUNDUP.  // BioWorld Today;6/17/2009, Vol. 20 Issue 115, p7 

    This section offers news briefs on financing of biotechnology companies. A $9 million financing round that includes a $5 million credit facility from MidCap Financial has been completed by CeNeRx BioPharma Inc. A prospectus to offer about 8.6 million units comprised of common shares and common...

  • Financings Roundup.  // BioWorld Today;2/14/2011, Vol. 22 Issue 30, p5 

    The article reports that SemBioSys Genetics Inc. has entered a commitment for up to 4 million Canadian dollars in financing, which would consist of bonds issuable in two tranches of 2 million Canadian dollars each and will issue detachable warrants convertible into common shares.

  • Other News To Note.  // BioWorld Today;4/5/2012, Vol. 23 Issue 66, p2 

    This section offers news briefs from the pharmaceutical biotechnology industry. A letter has been sent by activist shareholder Carl Icahn to Amylin Pharmaceuticals Inc. asserting his belief that a sale of the firm should be pursued by the company's board. An application to voluntary delist its...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics